Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > From a Linked in post

<< Previous

Bullboard Posts

Next >>

Comment by jh1970on Jun 06, 2024 9:16pm

150 Views

Post# 36076712

RE:From a Linked in post

Dirk Arnold

Asklepios Tumorzentrum Hamburg #atzhh

7h

So many interesting discussions at the poster board - and such a remarkable interest in GOBLET. Thank you, Oncolytics and AIO gGmbH team . GOBLET cohort 5 about to include our first patient.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China